These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25865153)

  • 21. Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.
    Onderdijk AJ; Ijpma AS; Menting SP; Baerveldt EM; Prens EP
    Br J Dermatol; 2015 Dec; 173(6):1536-9. PubMed ID: 26134667
    [No Abstract]   [Full Text] [Related]  

  • 22. Ustekinumab as therapy for psoriasis in a 2-year-old girl.
    Min MS; Shroff A; Rose S; Lebwohl M; Guttman-Yassky E
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e109-e110. PubMed ID: 26377248
    [No Abstract]   [Full Text] [Related]  

  • 23. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
    Dickson L; Menter A
    J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
    Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
    Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
    [No Abstract]   [Full Text] [Related]  

  • 25. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting.
    Llamas-Velasco M; Concha-Garzón MJ; García-Diez A; Daudén E
    Actas Dermosifiliogr; 2015; 106(6):470-6. PubMed ID: 25912374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of ustekinumab in palmoplantar pustulosis.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Uthurriague C; Paul C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e204-e206. PubMed ID: 29194805
    [No Abstract]   [Full Text] [Related]  

  • 27. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
    Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
    Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
    Fujita Y; Shinkuma S; Nomura T; Shimizu H
    Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful treatment of severe psoriasis in an adolescent with ustekinumab.
    AbuHilal M; Ho N
    Pediatr Dermatol; 2015; 32(3):377-80. PubMed ID: 25727845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
    Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
    Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
    J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
    [No Abstract]   [Full Text] [Related]  

  • 32. Clearance of annular pustular psoriasis with ustekinumab.
    Schnabel V; Broekaert SMC; Schön MP; Mössner R
    Eur J Dermatol; 2017 Jun; 27(3):296-297. PubMed ID: 28202422
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.
    De Keyser E; Busard CI; Lanssens S; Meuleman L; Hutten BA; Costanzo A; van den Reek JM; Zweegers J; Lambert J; Spuls PI
    Ther Drug Monit; 2019 Oct; 41(5):634-639. PubMed ID: 31107404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
    J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
    Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
    Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
    Hayashi M; Umezawa Y; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2014 Nov; 41(11):974-80. PubMed ID: 25346301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of superimposed linear psoriasis to ustekinumab: A case report.
    Weng HJ; Tsai TF
    Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D; Gregoriou S; Makris M; Ioannides D
    Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inverse psoriasis treated with ustekinumab.
    Campos MA; Varela P; Baptista A; Moreira AI
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27222277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of ustekinumab in a psoriasis patient with human T-cell leukemia/lymphotropic virus type 1 infection.
    Kazama M; Umezawa Y; Itoh M; Nobeyama Y; Ito T; Kikuchi S; Yanaba K; Asahina A; Nakagawa H; Ogasawara Y
    J Dermatol; 2017 Nov; 44(11):1334-1335. PubMed ID: 27864824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.